Latest News and Press Releases
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
December 09, 2024 16:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
December 09, 2024 16:05 ET
|
OncoCyte Corporation
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings – January 13-16, 2025, San Francisco, CA
Fluence Energy, Inc. Announces Convertible Notes Offering and Intention to Enter into Capped Call Transactions
December 09, 2024 16:01 ET
|
Fluence
ARLINGTON, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational...
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 09, 2024 16:01 ET
|
LENSAR, Inc.
ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors...
HealthEquity Reports Third Quarter Ended October 31, 2024 Financial Results
December 09, 2024 16:01 ET
|
HealthEquity, Inc.
Highlights of the third quarter include: Revenue of $300.4 million, an increase of 21% compared to $249.2 million in Q3 FY24.Net income of $5.7 million, compared to $14.7 million in Q3 FY24, with...
Protara Announces Proposed Public Offering
December 09, 2024 16:01 ET
|
Protara Therapeutics
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare...
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 09, 2024 16:01 ET
|
Biomea Fusion, Inc.
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and tolerability...
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
December 09, 2024 16:01 ET
|
Chimerix, Inc.
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
December 09, 2024 16:01 ET
|
Fate Therapeutics, Inc.
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach...
MYR Group Inc. to Attend Goldman Sachs Energy, CleanTech & Utilities Conference in January
December 09, 2024 16:00 ET
|
MYR Group, Inc.
THORNTON, Colo., Dec. 09, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure,...
- December 09, 2024 15:25 ET Organic & Natural Health Association’s 10th Annual Conference Explores Sustainability From an International Perspective
- December 09, 2024 15:11 ET Oscar Raposo Joins Scouting America as New Chief Financial Officer